Literature DB >> 1569304

Rhodococcus equi infection in patients with AIDS.

M Drancourt1, E Bonnet, H Gallais, Y Peloux, D Raoult.   

Abstract

Rhodococcus equi is an emerging opportunistic pathogen of HIV-I infected patients. It is an aerobic, Gram-positive coryneform bacterium which acts as a facultative intracellular micro-organism, multiplying in the phagosome of macrophages. Eighteen cases of R. equi infection in HIV-I positive patients have now been reported. Sixteen of these had pneumonia, of which 12 had cavitating lung lesions. A history of contact with farm animals, which are the primary hosts of R. equi, was found in only three patients. There was a delay in establishing a definite diagnosis in most cases as this depended upon the isolation of R. equi from sputum, bronchoalveolar lavage fluid, or blood. Treatment included surgical resection in five patients and erythromycin with a second antibiotic in 13 cases, but II of the 18 patients died from the infection. In this report we describe our experience of R. equi pneumonia in two AIDS patients and review the published cases of the disease in man.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1569304     DOI: 10.1016/0163-4453(92)92746-6

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  14 in total

1.  Nonhealing wound due to Rhodococcus equi in an apparently immunocompetent patient, revealing CD8+ T-lymphocyte deficiency.

Authors:  Eric Denes; Dominique Peignon-Orsoni; François-Xavier Terrade
Journal:  J Clin Microbiol       Date:  2010-09-29       Impact factor: 5.948

2.  A proteomic approach to investigate immunity against R. Equi in foals.

Authors:  P Roncada; L Bonizzi; R Fortin; M L Menandro; G F Greppi
Journal:  Vet Res Commun       Date:  2005-08       Impact factor: 2.459

3.  MICs of oxazolidinones for Rhodococcus equi strains isolated from humans and animals.

Authors:  T L Bowersock; S A Salmon; E S Portis; J F Prescott; D A Robison; C W Ford; J L Watts
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

4.  Emergence of rifampin-resistant Rhodococcus equi in an infected foal.

Authors:  S Takai; K Takeda; Y Nakano; T Karasawa; J Furugoori; Y Sasaki; S Tsubaki; T Higuchi; T Anzai; R Wada; M Kamada
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

5.  Rhodococcus equi peritonitis in continuous ambulatory peritoneal dialysis: a first in Australia.

Authors:  Omar Azzam; Amy Crowe; Cherian Sajiv; Basant Pawar
Journal:  BMJ Case Rep       Date:  2015-10-05

6.  Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease.

Authors:  Cesar Homero Gutiérrez-Aguirre; Olga Graciela Cantú-Rodríguez; Omar David Borjas-Almaguer; Oscar González-Llano; José Carlos Jaime-Pérez; Manuel Solano-Genesta; Miguel Gómez-Guijosa; Consuelo Mancias-Guerra; Luz Tarin; David Gómez-Almaguer
Journal:  Haematologica       Date:  2011-12-01       Impact factor: 9.941

7.  Tumour necrosis factor and interferon-gamma are required in host resistance against virulent Rhodococcus equi infection in mice: cytokine production depends on the virulence levels of R. equi.

Authors:  H Kasuga-Aoki; S Takai; Y Sasaki; S Tsubaki; H Madarame; A Nakane
Journal:  Immunology       Date:  1999-01       Impact factor: 7.397

8.  Identification of intermediately virulent Rhodococcus equi isolates from pigs.

Authors:  S Takai; N Fukunaga; S Ochiai; Y Imai; Y Sasaki; S Tsubaki; T Sekizaki
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

9.  Virulence of Rhodococcus equi isolates from patients with and without AIDS.

Authors:  S Takai; Y Sasaki; T Ikeda; Y Uchida; S Tsubaki; T Sekizaki
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

Review 10.  The medically important aerobic actinomycetes: epidemiology and microbiology.

Authors:  M M McNeil; J M Brown
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.